IL179149A0 - Therapeutic compounds: pyridine as scaffold - Google Patents

Therapeutic compounds: pyridine as scaffold

Info

Publication number
IL179149A0
IL179149A0 IL179149A IL17914906A IL179149A0 IL 179149 A0 IL179149 A0 IL 179149A0 IL 179149 A IL179149 A IL 179149A IL 17914906 A IL17914906 A IL 17914906A IL 179149 A0 IL179149 A0 IL 179149A0
Authority
IL
Israel
Prior art keywords
scaffold
pyridine
therapeutic compounds
therapeutic
compounds
Prior art date
Application number
IL179149A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Evertsson Emma Margareta
Walpole Christopher
Amin Kosrat
Broddefalk Johan
Desfosses Helene
Liu Ziping
Milburn Claire
Nilsson Karolina
Tremblay Maxime
Wei Zhong Yong
Yang Hua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32589804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL179149(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Evertsson Emma Margareta, Walpole Christopher, Amin Kosrat, Broddefalk Johan, Desfosses Helene, Liu Ziping, Milburn Claire, Nilsson Karolina, Tremblay Maxime, Wei Zhong Yong, Yang Hua filed Critical Astrazeneca Ab
Publication of IL179149A0 publication Critical patent/IL179149A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL179149A 2004-05-25 2006-11-09 Therapeutic compounds: pyridine as scaffold IL179149A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0401345A SE0401345D0 (sv) 2004-05-25 2004-05-25 Therapeutic compounds: Pyridine as scaffold
PCT/SE2005/000753 WO2005115986A1 (en) 2004-05-25 2005-05-20 Therapeutic compounds: pyridine as scaffold

Publications (1)

Publication Number Publication Date
IL179149A0 true IL179149A0 (en) 2007-03-08

Family

ID=32589804

Family Applications (1)

Application Number Title Priority Date Filing Date
IL179149A IL179149A0 (en) 2004-05-25 2006-11-09 Therapeutic compounds: pyridine as scaffold

Country Status (18)

Country Link
US (1) US20070225292A1 (enExample)
EP (1) EP1756060A1 (enExample)
JP (1) JP2008500336A (enExample)
KR (1) KR20070026540A (enExample)
CN (1) CN101001840A (enExample)
AR (1) AR049110A1 (enExample)
AU (1) AU2005247834A1 (enExample)
BR (1) BRPI0511531A (enExample)
CA (1) CA2565065A1 (enExample)
IL (1) IL179149A0 (enExample)
MX (1) MXPA06013538A (enExample)
NO (1) NO20065878L (enExample)
RU (1) RU2006145205A (enExample)
SE (1) SE0401345D0 (enExample)
TW (1) TW200607799A (enExample)
UY (1) UY28923A1 (enExample)
WO (1) WO2005115986A1 (enExample)
ZA (1) ZA200609765B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
JO2747B1 (en) 2005-07-26 2014-03-15 جلاكسو جروب ليمتد Vehicles
TW200804338A (en) * 2005-11-24 2008-01-16 Astrazeneca Ab New compounds
GB0524814D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
ES2596532T3 (es) 2006-03-16 2017-01-10 Second Genome, Inc. Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
EP2024349B1 (en) 2006-05-31 2017-08-02 AbbVie Inc. Compounds as cannabinoid receptor ligands and uses thereof
PL2041093T3 (pl) 2006-06-28 2010-09-30 Glaxo Group Ltd Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38
JP2010522760A (ja) 2007-03-28 2010-07-08 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての１，３−チアゾール−２（３ｈ）−イリデン化合物
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008144360A1 (en) 2007-05-18 2008-11-27 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
EP2070916A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
EP2070924A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
CA2737199A1 (en) 2008-09-16 2010-03-25 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
PL2485731T4 (pl) * 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
JPWO2014013951A1 (ja) * 2012-07-19 2016-06-30 日本曹達株式会社 ピリジン化合物および農園芸用殺菌剤
KR20140011780A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
JP2017500287A (ja) * 2013-11-06 2017-01-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体
AU2014347027A1 (en) 2013-11-06 2016-06-23 Bristol-Myers Squibb Company GSK -3 inhibitors
JP2019131470A (ja) * 2016-05-20 2019-08-08 石原産業株式会社 Ｎ−（４−ピリジル）ベンズアミド化合物又はその塩を有効成分として含有する有害生物防除剤
MA49068B1 (fr) 2017-04-27 2023-07-31 Ishihara Sangyo Kaisha Composé n-(4-pyridyl) nicotinamide ou sel de celui-ci
CN107880024A (zh) * 2017-12-11 2018-04-06 张玉玲 一种用于治疗炎症的大麻素受体激动剂及其合成方法
JP7890737B2 (ja) * 2019-11-25 2026-07-15 ジーティー ゲイン セラピューティクス エスアー ガラクトセレブロシダーゼの活性の変質に関連する状態におけるアリールおよびヘテロアリール化合物、ならびにそれらの治療的使用
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3166627D1 (en) * 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
DE3046871A1 (de) * 1980-12-12 1982-07-22 Dr. Karl Thomae Gmbh, 7950 Biberach Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
AU2002254107B2 (en) * 2001-03-05 2006-12-21 E. I. Du Pont De Nemours And Company Heterocyclic diamide invertebrate pest control agents
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
RU2006145205A (ru) 2008-06-27
UY28923A1 (es) 2005-12-30
BRPI0511531A (pt) 2008-01-02
NO20065878L (no) 2007-02-21
ZA200609765B (en) 2008-08-27
EP1756060A1 (en) 2007-02-28
AU2005247834A1 (en) 2005-12-08
CA2565065A1 (en) 2005-12-08
AR049110A1 (es) 2006-06-28
WO2005115986A1 (en) 2005-12-08
JP2008500336A (ja) 2008-01-10
TW200607799A (en) 2006-03-01
SE0401345D0 (sv) 2004-05-25
CN101001840A (zh) 2007-07-18
US20070225292A1 (en) 2007-09-27
KR20070026540A (ko) 2007-03-08
MXPA06013538A (es) 2007-01-26

Similar Documents

Publication Publication Date Title
ZA200609765B (en) Therapeutic compounds: pyridine as scaffoid
GB0423554D0 (en) Therapeutic compounds
EP1730148A4 (en) USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
GB0518390D0 (en) Therapeutic compounds
ZA200609542B (en) Therapeutic compounds
GB0518237D0 (en) Therapeutic compounds
GB0509326D0 (en) Therapeutic compounds
GB0509573D0 (en) Therapeutic compounds
IL179603A0 (en) Pyrrolopyridine derivatives
GB0518361D0 (en) Therapeutic compounds
GB0522881D0 (en) Therapeutic compounds
GB0509405D0 (en) Therapeutic compounds
GB0420424D0 (en) Therapeutic compounds
GB0513747D0 (en) Therapeutic compounds
GB0522130D0 (en) Therapeutic compounds
GB0526107D0 (en) Therapeutic Compounds
GB0518235D0 (en) Therapeutic compounds
GB0427138D0 (en) Therapeutic compounds
HK1100341A (en) Therapeutic compounds: pyridine as scaffold
PL1688129T3 (pl) Nowy preparat terapeutyczny
GB0423767D0 (en) Therapeutic compounds
GB0417560D0 (en) Therapeutic compounds
ZA200609864B (en) Pyrrolopyridine derivatives
GB0608269D0 (en) Therapeutic compounds
HK1100179A (en) Therapeutic compounds: pyridine n oxide scaffold